We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
+0.22%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.87B
AUM Growth
-$81.8M
Cap. Flow
+$153M
Cap. Flow %
5.32%
Top 10 Hldgs %
73.56%
Holding
37
New
4
Increased
20
Reduced
3
Closed
9

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$84.9M
2
PCVX icon
Vaxcyte
PCVX
+$78.9M
3
RVMD icon
Revolution Medicines
RVMD
+$62.5M
4
JANX icon
Janux Therapeutics
JANX
+$59M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$54.3M

Top Sells

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$84.6M
2
ARVN icon
Arvinas
ARVN
+$57.6M
3
IMVT icon
Immunovant
IMVT
+$38.9M
4
CGEM icon
Cullinan Oncology
CGEM
+$38.9M
5
MRUS
Merus
MRUS
+$36.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$420M 14.61%
5,363,379
+363,379
+7% +$33.9M
ACLX
2
DELISTED
Arcellx
ACLX
$335M 11.66%
4,371,601
+371,601
+9% +$32.1M
ARGX icon
3
argenx
ARGX
$57.4B
$296M 10.3%
481,305
+931
+0.2% +$546K
RVMD icon
4
Revolution Medicines
RVMD
$40.2B
$287M 9.97%
6,553,111
+1,239,022
+23% +$62.5M
JANX icon
5
Janux Therapeutics
JANX
$935M
$188M 6.55%
3,515,986
+1,115,412
+46% +$59M
TARS icon
6
Tarsus Pharmaceuticals
TARS
$2.56B
$140M 4.88%
2,531,896
+91,451
+4% +$4.15M
EWTX icon
7
Edgewise Therapeutics
EWTX
$4.39B
$120M 4.17%
4,493,929
+1,704,757
+61% +$54.3M
PCVX icon
8
Vaxcyte
PCVX
$7.89B
$116M 4.05%
1,422,787
+795,055
+127% +$78.9M
ONC
9
BeOne Medicines Ltd
ONC
$33.8B
$114M 3.96%
616,024
+415,688
+207% +$84.9M
CRNX icon
10
Crinetics Pharmaceuticals
CRNX
$8.86B
$97.7M 3.4%
1,910,761
-605,925
-24% -$33.9M
MLTX icon
11
MoonLake Immunotherapeutics
MLTX
$1.59B
$96M 3.34%
1,772,211
+840,731
+90% +$42.9M
IRON icon
12
Disc Medicine
IRON
$2.83B
$95M 3.3%
1,497,720
– –
MRUS
13
DELISTED
Merus
MRUS
$71.1M 2.47%
1,689,922
-764,995
-31% -$36.7M
VERA icon
14
Vera Therapeutics
VERA
$2.54B
$60.8M 2.11%
1,437,339
+340,488
+31% +$15.1M
APGE icon
15
Apogee Therapeutics
APGE
$10.2B
$58.2M 2.02%
1,283,766
+581,949
+83% +$29.7M
OLMA icon
16
Olema Pharmaceuticals
OLMA
$1.02B
$42.6M 1.48%
7,304,970
+1,801,370
+33% +$18M
PLRX icon
17
Pliant Therapeutics
PLRX
$67.5M
$42.1M 1.47%
3,197,050
+92,564
+3% +$1.26M
IMTX icon
18
Immatics
IMTX
$1.24B
$38.5M 1.34%
5,414,409
+1,509,547
+39% +$13M
COGT icon
19
Cogent Biosciences
COGT
$6.79B
$38.4M 1.33%
4,917,412
+307,650
+7% +$3.07M
SYRE icon
20
Spyre Therapeutics
SYRE
$8.87B
$35.6M 1.24%
1,527,205
+259,624
+20% +$7.61M
VRDN icon
21
Viridian Therapeutics
VRDN
$2.13B
$34.9M 1.21%
1,820,079
-1,075,610
-37% -$23.4M
YMAB
22
DELISTED
Y-mAbs Therapeutics
YMAB
$33.2M 1.15%
4,236,346
+150,000
+4% +$1.83M
ERAS icon
23
Erasca
ERAS
$6.63B
$27M 0.94%
10,752,354
+84,213
+0.8% +$231K
TECX
24
Tectonic Therapeutic
TECX
$573M
$22.4M 0.78%
+485,105
New +$20.5M
LENZ
25
LENZ Therapeutics
LENZ
$172M
$22.2M 0.77%
+770,455
New +$23.5M
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
WTC
WhitTier Trust Company Reno, Nevada $4.87B AUM 25.35% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MSRPS
Maryland State Retirement & Pension System Baltimore, Maryland $4.92B AUM 28.48% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return

Paradigm Biocapital Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Paradigm Biocapital Advisors held 37 positions worth $2.87B, down 2.8% from $2.96B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Paradigm Biocapital Advisors deployed $153M of net new capital in Q4 2024, opening 4 new positions and adding to 20 existing holdings. Its largest new stake was LENZ Therapeutics: 770,455 shares worth $22.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.

On the sell side, the largest reduction was Merus, an estimated $36.7M trimmed.

  • Paradigm Biocapital Advisors's largest Q4 2024 buy was LENZ Therapeutics: 770,455 shares worth $22.2M.
  • Paradigm Biocapital Advisors added most to BeOne Medicines Ltd in Q4 2024, an estimated $84.9M increase.
  • Paradigm Biocapital Advisors's biggest Q4 2024 reduction was Merus, cutting an estimated $36.7M.
  • Paradigm Biocapital Advisors fully exited Kura Oncology in Q4 2024, selling an estimated $84.6M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 74% of its $2.87B portfolio in Q4 2024.
  • Paradigm Biocapital Advisors opened 4 new positions and closed 9 in Q4 2024.
  • Paradigm Biocapital Advisors's portfolio value fell 2.8% quarter-over-quarter to $2.87B.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.